UNSPSC 51162327: Ammonium chloride/diphenhydramine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162327 Ammonium chloride/diphenhydramine is a Commodity code that in practice captures emergency-response pharmaceuticals and over-the-counter health products procured by state and local health agencies, counties, and cooperative purchasing alliances to support public health and community safety initiatives. State and local issuing bodies use this code to source naloxone, drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and RFP processes. The work spans direct product procurement with quarterly or regular delivery schedules, compliance with cGMP and FDA requirements, and integration with authorized pharmaceutical wholesalers. Counties and state cooperative purchasing entities dominate recent activity, with issuing bodies managing their own procurement or administering multistate cooperative agreements that serve multiple jurisdictions simultaneously.

Recent opportunities show activity concentrated in Florida and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2026. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Both solicitations require vendors to demonstrate FDA compliance, maintain comprehensive insurance, and provide detailed product information with pricing through authorized wholesaler channels; the MMCAP RFP emphasizes price competitiveness at 75 percent of evaluation weight and requires a 3 percent administrative fee on all contract purchases.